FURKA A. Amino acid tester libraries – 4, 43

GRENN L. Solid-phase synthesis of a 2-amino-4(3H)-quinazolinone library – 7-8, 25

GRIFTHS M.C. The growing prominence of containment chemistry in the pharmaceutical industry - The Worldwide Pharma Chem Directory: 27

GRIMBERGEN R.F.P. Continuous developments in classical resolution: Dutch resolution and asymmetric transformation – 4, 17

HALL L.A. An integrated high throughput workflow for pre-formulations: Polymorph and salt selection studies – 7-8, 10

HALL R.W. Stereoselective enolate formation using lithium amides – 11-12, 4

HANKO R. Custom manufacturing for the pharmaceutical industry - 11-12, 26

HELD P. New combination: 96/384 well format for drug discovery – 4, 38

HERLAM G. From laboratory to marketplace. Comprehensive information on pharmaceuticals in STN databases – 10, 24

HEWES I.D. High throughput experimentation for materials: An Advanced technology program technology cluster – 7-8, 20

HIRANI B.R. A brief review on commercial potential of coumarins – 10, 50

HONEYWELL Honeywell Research & Life Science Solutions – A significant supplier to the industry – 5, 71

HONG B. Synthesis and structure activity relationship of novel chiral ligands for the glycine-reuptake transporter Type-2 (GlyT-2) – 6, 38

HOPPER A. Synthesis and structure activity relationship of novel chiral ligands for the glycine-reuptake transporter Type-2 (GlyT-2) – 6, 38

ISAKKA K. Single-enantiomer drugs: Starting materials and intermediates – 9, 42

INTERCHEM CORPORATION USA Bringing you a world of chemistry – 1-2, 23

ISAAC M. Synthesis and structure activity relationship of novel chiral ligands for the glycine-reuptake transporter Type-2 (GlyT-2) – 6, 38

ISOCHEM Dedicated hydrazine research unit opens in Lyons - 11-12, 10

ISOCHROM Isomeric evaluation and synthesis of biologically active pyrazines – 1-2, 62

ISOUX T. A novel high throughput workflow for pre-formulations: Polymorph and salt selection studies – 7-8, 10

IVANENKOVA A. Intelligent machine learning technologies in pre-synthetic combinatorial design – 4, 68

IVASHCHENKO A.A. Intelligent machine learning technologies in pre-synthetic combinatorial design – 4, 68

JANUARY/FEBRUARY 2004

JULICH S. Bringing you a world of chemistry – INTERCHEM CORPORATION USA

JOKSCH B. Fingerprinting surfactants using dynamic surface tension measurement – 6, 21

JELL D. Novel approach to drug discovery in PLVA – Establishing of HTS unit and unique compound library – 6, 64

JENNEN G. CALU & Genius: Weighing in workbench automation – 4, 38

JOHANSSON J. Ni LaView™ and Vision products monitor pharmaceutical processes – 7-8, 4

JOKSCH B. CALU & Genius: Weighing in workbench automation – 4, 38

KAPTEIN B. Continuous developments in classical resolution: Dutch resolution and asymmetric transformation – 4, 17

KELLOGG R.M. Continuous developments in classical resolution: Dutch resolution and asymmetric transformation – 4, 17

KHAN M.K. Development of dendrimer-gold radioactive nanocomposites to treat cancer microvasculature – 4, 94

KILLWORTH D. Leadership in fine chemicals – 1-2, 10


KNIEPER K. Solid phase indole synthesis – 6, 4

KOUL V.K. A brief review on commercial potential of coumarins – 10, 50

KOULOURIS A. Solid phase indole synthesis – 6, 4

KULOUIS A. Optimize development and manufacturing of API’s with batch process simulations – 5, 58

KUDLA T. An integrated high throughput workflow for pre-formulations: Polymorph and salt selection studies – 7-8, 10

KUSCHEL M. Blood sampling and Washer Elx405 Select New combination: 96/384 well format for drug discovery – 4, 38

LACUSKY P. Training in a lean enterprise...Preparing for success in an organization transitioning to lean management – 1-2, 89

LAMIN D. The first recyclable detergent component: Phosphates – 9, 54

KLAUS A. Development of dendrimer-gold radioactive nanocomposites to treat cancer microvasculature – 4, 94

KLEIN W. Leadership in fine chemicals – 1-2, 10

KUHN V.K. A brief review on commercial potential of coumarins – 10, 50

KLEIN T. Development of dendrimer-gold radioactive nanocomposites to treat cancer microvasculature – 4, 94

KLIINE K. A novel high throughput workflow for pre-formulations: Polymorph and salt selection studies – 7-8, 10

KLUFT W. Exceptionally active and selective ketone hydrogenation catalysts – 4, 24

KLUFT W. From simulation to implementation: A lean success story in a regulated industry – 9, 46

KLUFT W. Crystalline sorbitol. A pharmaceutical device company's success story in a regulated environment – 4, 64

KLUFT W. Lean pharmacovigilance: A review of the drug safety process from a lean perspective – 6, 10

KLUFT W. Total Productive Manufacturing... The evolution of a maintenance based tool to a critical operational construct – 7-8, 55

KLUFT W. Back from the brink: From simulation to implementation. A lean success story in a regulated industry – 9, 46

KLUFT W. Back from the brink: From simulation to implementation. A lean success story in a regulated industry – 9, 46

KLUFT W. Back from the brink: From simulation to implementation. A lean success story in a regulated industry – 9, 46

KLUFT W. Back from the brink: From simulation to implementation. A lean success story in a regulated industry – 9, 46

KLUFT W. Back from the brink: From simulation to implementation. A lean success story in a regulated industry – 9, 46

KLUFT W. Back from the brink: From simulation to implementation. A lean success story in a regulated industry – 9, 46

KLUFT W. Back from the brink: From simulation to implementation. A lean success story in a regulated industry – 9, 46

KLUFT W. Back from the brink: From simulation to implementation. A lean success story in a regulated industry – 9, 46

KLUFT W. Back from the brink: From simulation to implementation. A lean success story in a regulated industry – 9, 46

INOTRA M. Asymmetric hydrogenation applied to industrial processes: a convenient synthesis of panexetone - 11-12, 13

MAHFOUZ H. Synthetic and structure activity relationship of novel chiral ligands for the glycine-reuptake transporter Type-2 (GlyT-2) – 6, 38

MAJID A. Hydrogenation using monodentate transition metal complexes – 7-8, 55

MÁGERLEIN W. Managing Microsoft® Excel templates and spreadsheets in a controlled, compliant environment – 7-8, 65

MACLEAN N. Cambrex Corporation (Interview) – 11-12, 92

MACLEAN N. Cambrex Corporation (Interview) – 11-12, 92

MANCONI S. An integrated high throughput workflow for pre-formulations: Polymorph and salt selection studies – 7-8, 10

MAREK L. Development of dendrimer-gold radioactive nanocomposites to treat cancer microvasculature – 4, 94

MAREK L. Development of dendrimer-gold radioactive nanocomposites to treat cancer microvasculature – 4, 94

MARENKO M. Arylamino derivatives applied to industrial processes: a convenient synthesis of panexetone - 11-12, 13

MASUI C. An integrated high throughput workflow for pre-formulations: Polymorph and salt selection studies – 7-8, 10

MCALLUM K. Synthesis and structure activity relationship of novel chiral ligands for the glycine-reuptake transporter Type-2 (GlyT-2) – 6, 38

MEAD E. Synthesis and structure activity relationship of novel chiral ligands for the glycine-reuptake transporter Type-2 (GlyT-2) – 6, 38

MESNER L. Synthesis and structure activity relationship of novel chiral ligands for the glycine-reuptake transporter Type-2 (GlyT-2) – 6, 38

MILLER D.J. Three-phase bath oils - An eye-catching application of microorganisms – 3, 58

MILLER D.J. Three-phase bath oils - An eye-catching application of microorganisms – 3, 58

MINC L. Development of dendrimer-gold radioactive nanocomposites to treat cancer microvasculature – 4, 94

MINNARDA A.J. Affordable asymmetric olefin hydrogenation using monodentate phosphoramides – 9, 33

MOORE M.G. Mid-2003 global business of chemistry. Situation and outlook – 7-8, 60

MOORE M.G. Mid-2003 global business of chemistry. Situation and outlook – 7-8, 60

MOORE M.G. Mid-2003 global business of chemistry. Situation and outlook – 7-8, 60

MOORE M.G. Mid-2003 global business of chemistry. Situation and outlook – 7-8, 60

MOORE M.G. Mid-2003 global business of chemistry. Situation and outlook – 7-8, 60

MOORE M.G. Mid-2003 global business of chemistry. Situation and outlook – 7-8, 60
INDEX

Quality – What does it really mean to you, your organisation and your customers? Part two – 1-12, 92
NIEUWENHUIZEN I.J.W. Continuous developments in classical resolution: Dutch resolution and asymmetric transformation – 4, 17
NIGAVEKAR S.S. Development of dendrimer-gold radioactive nanocomposites to treat cancer microvasculature – 4, 94
NIKOLSKY Y.I. Intelligent machine learning technologies in pre-synthetic combinatorial design – 4, 68
O’BRIEN A. Synthesis and structure activity relationship of novel chiral ligands for the glycine-reuptake transporter Type-2 (GlyT-2) – 6, 38
OBERRAUCH G. Zambon Corporation (Interview) – 5, 26
ORGNYAVOV Y. Synthesis and structure activity relationship of novel chiral ligands for the glycine-reuptake transporter Type-2 (GlyT-2) – 38
OSENCHINSKY S. Rapid compound purity screening using the Nanostream Veloce system – 7-8, 7
PATEL P. Rapid compound purity screening using the Nanostream Veloce system – 7-8, 7
PENA D. Affordable asymmetric olefin hydrogenation using monodentate phosphoramidites – 9, 33
PERLMUTTER B.A. Evaluating fine-cake pressure filtration using the BHS Autopress technology - The Worldwide Pharma Chem Directory, 4
PETERSEN A. From laboratory to marketplace. Comprehensive information on pharmaceuticals in STN databases – 10, 24
PETRESA Company Profile – 3, 62
PETRIDES D.P. Optimize development and manufacturing of APL’s with batch process simulators – 5, 58
PINCHARD L. Continuous improvements in chiral synthesis – 6, 23
POKROPSKI E. Compliant Operations: A lean approach to meeting internal and external regulatory requirements – 3, 22
POTAPCHUK L. Using the Nanostream Veloce system – 7-8, 10
RATIONAL A. Silicone excipients for aesthetically superior and substantive topical pharmaceutical formulations – 5, 17
SHELTON D.L. Strategies for effective control of biofilms and surface-associated microorganisms – 5, 66
SINGH M.P. A brief review on commercial potential of coumarins. – 10, 50
SLASSI A. Synthesis and structure activity relationship of novel chiral ligands for the glycine-reuptake transporter Type-2 (GlyT-2) – 6, 38
SONNENSCHEIN H. Kinetic resolutions of alcohols by combining lipase catalysis and fluorous phase labeling – Separation of enantiomers by extraction – 6-7, 32
SONNEVELD A. A partner of choice for the pharma industry (Interview) – 1-2, 26
STRONG J.G. BINAP – The people’s ligand for chiral chemistry – 6, 20
SWIFT T.K. Mid-2003 global business of chemistry. Situation and outlook – 7-8, 60
TEHIM A. Synthesis and structure activity relationship of novel chiral ligands for the glycine-reuptake transporter Type-2 (GlyT-2) – 6, 38
THEIL F. Kinetic resolutions of alcohols by combining lipase catalysis and fluorous phase labeling – Separation of enantiomers by extraction – 6, 32
THOMMEN M. Synthesis technology sourcing from reliable technology providing companies – A serious, flexible, cost-efficient, scalable, low risk option – 4, 6
TANGKULISAN A. An integrated high throughput workflow for pre-formulations: Polymorph and salt selection studies – 7-8, 10
TERZIAN J. Novel type-1 (GlyT-2) – 6, 38
THORNTON C. The first recyclable detergent component: Phosphates – 9, 54
UNG K.Q. An integrated high throughput workflow for pre-formulations: Polymorph and salt selection studies – 7-8, 10
UTIGER L. New paths to capture value in custom manufacturing – 10, 8
VAISHNAV P. Nitrogen regulation of biosynthesis of antibiotics and other secondary metabolic products – 10, 92
VAJHALA S. Rapid compound purity screening using the Nanostream Veloce system – 7-8, 7
VAN DEN BERG M. Affordaible asymmetric olefin hydrogenation using monodentate phosphoramidites – 9, 33
VAN DER JAGT K.E. Development of dendrimer-gold radioactive nanocomposites to treat cancer microvasculature – 4, 94
VAN DEN BERG M. Affordable asymmetric olefin hydrogenation using monodentate phosphoramidites – 9, 33
VAN DER JAGT K.E. Worker exposure assessment for biocidal products under European legislation – 10, 62
WEBER C. Solid-phase synthesis of a 2-amino-4(3H)-quinazolinone library – 7-8, 25
WELLER J.L. Scope and potential impact of the EU’s new “REACH” chemical proposal- 11-12, 50
WELLER P.F. “Make to Stock” contractual agreement between Aventis and Famar – 9, 51
WOLTERMANN C.J. Amazing base - Mesityllithium, MESLI – 1-2, 6
WOLTERMANN C.J. New, stable, protected functionalized chiral catalysts – 11-12, 8
WONG J. Continuous parallel process for the glycine-reuptake transporter Type-2 (GlyT-2) – 6, 38
WÜL C. A brief review on the glycine-reuptake transporter Type-2 (GlyT-2) – 6, 38
YOON J. Continuous development process for (S)-3-hydroxy-γ-butyrolactone, (S)-HCBL – 5, 13
ZAMBRON GROUP Investing in solid performance for long-lasting partnerships – 11-12, 8
ZHANG L. Rapid compound purity screening using the Nanostream Veloce system – 7-8, 7
ZIEBOLZ B. Downstream proteases for biopharmaceuticals production – 10, 16
ZIEGERT R.E. Solid phase indole synthesis – 6, 4
ZINSSER W. CALI B. Genius: Weighing in workbench automation – 4, 38

ZUMBACH H. Agreement between Aventis and Famar to establish an active pharmaceutical ingredient (API) formulation unit – 11, 36
ZUMBACH H. Agreement between Aventis and Famar to establish a new, stable, protected functionalized chiral catalysts – 11-12, 8